[ad_1]
Image copyright
SEAN ELIAS-OXFORD VACCINE TEST
This research work started in January of this year.
The president of the pharmaceutical giant AstraZeneca, Pascal Soriot, recently said that a new coronary pneumonia vaccine may be available for limited use later this year.
The Oxford University team is developing related vaccines. If valid, AstraZeneca agrees to manufacture and distribute it.
Suboko said the current demand for vaccines to beat the new coronavirus is “urgent.” Last week, the first human European vaccine trial was conducted in Oxford.
He said the Oxford University team’s track record is very good and technologically advanced, and AstraZeneca will know if its vision will be realized before June or July.
To this end, AstraZeneca is working with the vaccine development team at the Jenner Institute at Oxford University, and relevant test data may be released in mid-June.
AstraZeneca President Su Boke said the new coronary pneumonia vaccine may be available for limited use later this year.
They plan to deliver the vaccine for quick approval in the fourth quarter of 2020 for limited use later this year.
Suboko said: “We hope that through cooperation between multiple parties, we can accelerate the globalization of vaccines to combat this virus and protect people from the deadliest pandemic experienced by this generation.”
Sir John Bell, Regius professor of medicine at Oxford University, told the BBC’s Fourth Today program that AstraZeneca’s consent was important because it helped “we know if we can This vaccine is manufactured and distributed in the UK and throughout the world world “.
Image copyright
Getty Images
Sir Bell said the challenge is that after the vaccine is approved by the regulatory body, “you may not have to go back to square one, but focus on how to mass produce.”
If the R&D achievements of the Oxford University team are effective, they will work with AstraZeneca to have a production capacity of tens of millions of agents by the end of the year.
“Our vaccine production capacity in the UK is not up to the required level, and we will work with AstraZeneca to significantly increase production capacity,” said Bell.
British Commerce Secretary Alok Sharma said AstraZeneca’s agreement with Oxford University is an “important step” in any manufacturing process.
“This will also ensure that if the vaccine developed by the Jenner Institute at Oxford University is effective, the vaccine will be available as soon as possible, protecting thousands of people,” he added.
After AstraZeneca announced this decision, the company’s share price rose nearly 3%.
